Shaun Patterson
@shaundavid01.bsky.social
📤 68
📥 59
📝 17
Postdoctoral researcher focused on CML and AML. University of Glasgow based.
Our work on BCR::ABL1 in bone marrow vs. peripheral blood to predict treatment free remission in chronic myeloid leukaemia is now published in Leukemia! Jointly authored with TU Dresden and the Hammersmith.
www.nature.com/articles/s41...
@pogresearch.bsky.social
@uofgcancersciences.bsky.social
loading . . .
Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow -...
Leukemia - Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or...
https://www.nature.com/articles/s41375-025-02853-7
2 months ago
1
3
2
It was great to present our abstract focusing on the predictive power of intronic variants for treatment-free remission in CML patients at
@ash.hematology.org
2025. Thank you to
@bscb-official.bsky.social
for supporting my conference attendance this year and
@cancerresearchuk.org
grant funding
3 months ago
1
0
0
Our collaborative manuscript with TU Dresden is now available as a preprint! As a joint first author with Andrea Gottschalk, I was involved in a study combining our PCR-based evaluation of BCR::ABL1 levels with mathematical modelling approaches to predict TFR.
www.medrxiv.org/content/10.1...
loading . . .
BCR::ABL1 evaluation in bone marrow is no more predictive of TFR success than from peripheral blood
Background: Despite the excellent survival for chronic myeloid leukaemia (CML) patients treated with tyrosine kinase inhibitors (TKI), most CML patients report poorer quality of life due to TKI side-e...
https://www.medrxiv.org/content/10.1101/2025.09.01.25334821v1
6 months ago
1
0
0
I also had an e-poster focused on the T-cell receptor repertoire as a predictor for treatment-free remission at the
#BSH
conference in Glasgow
#CML
#TFR
11 months ago
0
0
0
Congratulations to Isla Nosratzadeh for presenting her excellent work on assessing mesenchymal stem cell senescence in CML patients from the DESTINY trial as a means of identifying biomarkers for treatment-free remission. She delivered an interesting and clear talk!
#CML
#TFR
#MSCs
11 months ago
0
0
0
🤯
add a skeleton here at some point
about 1 year ago
0
0
0
Let's encourage (x) users to move over in urgency! As a society, we cannot support these tech oligarchs' platforms. I don't want this feed to be political, but there are certain times where it is essential.
about 1 year ago
1
1
0
Two potential fundraising challenges for 2025 - Staffin triathlon (I've never done one of these) or another marathon? Didn't get a place in Berlin marathon again, so I'll keep trying!
about 1 year ago
0
0
0
I was delighted to present our work on lymphoid populations in CML patients who aimed for TFR in the DESTINY trial. Thank you to Prof Mhairi Copland for leading this project and to the patients who donated bone marrow samples for the trial.
#ASH24
@ash-hematology.bsky.social
over 1 year ago
1
5
0
Another day of
#ASH24
- presenting today at 5:15pm 🤓
over 1 year ago
0
0
0
Great poster sessions today at
#ASH2024
over 1 year ago
0
0
0
Interesting sessions on clonal hematopoiesis to kick off
#ASH24
over 1 year ago
0
0
0
Marking my new Bluesky account at the start of
#ASH24
over 1 year ago
0
3
0
you reached the end!!
feeds!
log in
